BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 22886526)

  • 1. Wnt pathway activity confers chemoresistance to cancer stem-like cells in a neuroblastoma cell line.
    Vangipuram SD; Buck SA; Lyman WD
    Tumour Biol; 2012 Dec; 33(6):2173-83. PubMed ID: 22886526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia.
    Alakhova DY; Zhao Y; Li S; Kabanov AV
    PLoS One; 2013; 8(8):e72238. PubMed ID: 23977261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties.
    Su YJ; Lin WH; Chang YW; Wei KC; Liang CL; Chen SC; Lee JL
    Oncotarget; 2015 Nov; 6(35):38029-45. PubMed ID: 26515729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA-binding motif protein 5 negatively regulates the activity of Wnt/β-catenin signaling in cigarette smoke-induced alveolar epithelial injury.
    Hao YQ; Su ZZ; Lv XJ; Li P; Gao P; Wang C; Bai Y; Zhang J
    Oncol Rep; 2015 May; 33(5):2438-44. PubMed ID: 25738917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway.
    Flahaut M; Meier R; Coulon A; Nardou KA; Niggli FK; Martinet D; Beckmann JS; Joseph JM; Mühlethaler-Mottet A; Gross N
    Oncogene; 2009 Jun; 28(23):2245-56. PubMed ID: 19421142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Fluorouracil upregulates the activity of Wnt signaling pathway in CD133-positive colon cancer stem-like cells.
    Deng YH; Pu XX; Huang MJ; Xiao J; Zhou JM; Lin TY; Lin EH
    Chin J Cancer; 2010 Sep; 29(9):810-5. PubMed ID: 20800023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/β-catenin pathway.
    Zhou W; Li Y; Gou S; Xiong J; Wu H; Wang C; Yan H; Liu T
    Oncotarget; 2015 Nov; 6(35):37557-69. PubMed ID: 26485754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wnt signalling is a bi-directional vulnerability of cancer cells.
    Duffy DJ; Krstic A; Schwarzl T; Halasz M; Iljin K; Fey D; Haley B; Whilde J; Haapa-Paananen S; Fey V; Fischer M; Westermann F; Henrich KO; Bannert S; Higgins DG; Kolch W
    Oncotarget; 2016 Sep; 7(37):60310-60331. PubMed ID: 27531891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents.
    Vangipuram SD; Wang ZJ; Lyman WD
    Pediatr Blood Cancer; 2010 Mar; 54(3):361-8. PubMed ID: 19927294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial-mesenchymal transition.
    Zhang B; Yang Y; Shi X; Liao W; Chen M; Cheng AS; Yan H; Fang C; Zhang S; Xu G; Shen S; Huang S; Chen G; Lv Y; Ling T; Zhang X; Wang L; Zhuge Y; Zou X
    Cancer Lett; 2015 Jan; 356(2 Pt B):704-12. PubMed ID: 25449432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
    Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
    Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin.
    Quan MF; Xiao LH; Liu ZH; Guo H; Ren KQ; Liu F; Cao JG; Deng XY
    World J Gastroenterol; 2013; 19(43):7680-95. PubMed ID: 24431896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors.
    Ayadi M; Bouygues A; Ouaret D; Ferrand N; Chouaib S; Thiery JP; Muchardt C; Sabbah M; Larsen AK
    Oncotarget; 2015 Jul; 6(21):18518-33. PubMed ID: 26041882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of WNT signaling reduces differentiation and induces sensitivity to doxorubicin in human malignant neuroblastoma SH-SY5Y cells.
    Suebsoonthron J; Jaroonwitchawan T; Yamabhai M; Noisa P
    Anticancer Drugs; 2017 Jun; 28(5):469-479. PubMed ID: 28240680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.
    Tang Y; Berlind J; Mavila N
    Cell Commun Signal; 2018 Mar; 16(1):9. PubMed ID: 29530069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway.
    Sartelet H; Imbriglio T; Nyalendo C; Haddad E; Annabi B; Duval M; Fetni R; Victor K; Alexendrov L; Sinnett D; Fabre M; Vassal G
    Histopathology; 2012 Jun; 60(7):1144-55. PubMed ID: 22394107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations.
    Yang Z; Zhang L; Ma A; Liu L; Li J; Gu J; Liu Y
    PLoS One; 2011; 6(12):e28405. PubMed ID: 22145042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rab11a sustains GSK3β/Wnt/β-catenin signaling to enhance cancer progression in pancreatic cancer.
    Yu L; Li X; Li H; Chen H; Liu H
    Tumour Biol; 2016 Oct; 37(10):13821-13829. PubMed ID: 27481517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of CD133 promotes drug resistance in C6 glioma cells.
    Angelastro JM; Lamé MW
    Mol Cancer Res; 2010 Aug; 8(8):1105-15. PubMed ID: 20663862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
    Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
    Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.